CELL DERIVED MICROPARTICLES: METHOD DEVELOPMENT, AND CLINICAL AND EXPERIMENTAL STUDIES

AKADEMISK AVHANDLING
som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras i Aulan, Danderyds sjukhus, entréplan

Fredagen den 8 mars 2013, kl 09.00

av
Fariborz Mobarrez

Huvudhandledare:
Docent Håkan Wallén
Karolinska Institutet
Institutionen för kliniska vetenskaper,
Danderyds Sjukhus
Enheten för kardiovaskulär medicin

Bihandledare:
Docent Jovan Antovic
Karolinska Institutet
Institutionen för molekylär medicin och kirurgi
Enheten för klinisk kemi,
Karolinska Universitets Sjukhuset, Solna

Docent Nils Egberg
Karolinska Institutet
Institutionen för molekylär medicin och kirurgi
Enheten för klinisk kemi,
Karolinska Universitets Sjukhuset, Solna

Fakultetsopponent:
Prof. Alison Goodall
Department of Cardiovascular Sciences,
University of Leicester, UK

Betygsnämnd:
Docent Angela Silveira
Karolinska Institutet
Institutionen för medicin, Solna
Enheten för aterosklerosforskning

Docent Anders Gottsäter
Kärlkliniken
Skånes universitetssjukhus, Malmö

Prof. Tomas Lindahl
Linköpings Universitet
Institutionen för klinisk och experimentell medicin
Klinisk kemi

Stockholm 2013
ABSTRACT

Background
Cell derived microparticles (MP) are released from the cell membrane upon activation or apoptosis. They resemble their parent cell by exposing similar proteins or surface receptors. This enables identification of their cellular origin. MP are considered to facilitate cross-talk between cells, and to be involved in coagulation, inflammation and vascular function. Elevated circulating MP have been shown in previous studies. Assessment of MP is, however, difficult due to methodological issues.

Aims
To evaluate pre-analytical procedures and a flow cytometric method for detection of microparticles. To study the effects of statin treatment and inflammation on phenotype and functional properties of microparticles.

Methods and Results
In Paper I we describe a flow cytometric method for measurements of platelet derived microparticles (PMP) exposing CD62P or CD142. Mean fluorescence intensity measurements were more reproducible than concentration measurements. The presence of platelet fragments could be detected with the peptide phalloidin. This approach can be used as a quality control of samples. Samples frozen and stored as platelet-free plasma generated lowest number of platelet fragments upon flow cytometric analysis. Using our flow cytometric protocol we found two times higher exposure of CD62P and CD142 on PMP in plasma from type 1-diabetes patients compared to healthy controls.

In Paper II and III we investigated the effects of atorvastatin on MP. Nineteen patients with atherothrombotic disease were randomized to treatment with atorvastatin or placebo in a cross-over fashion. Thrombin generation and exposure of CD61, CD62P, CD142 and phosphatidylserine (PS) were assessed on PMP (Paper II). Endothelial derived MP (EMP) were assessed by CD144 or CD144+CD142+ exposure (Paper III). During atorvastatin treatment both thrombin generation and exposure of CD61, CD62P, and CD142 on PMP decreased. No effect was seen on PS exposure. Furthermore, we demonstrated that MP enhanced thrombin generation through PS and CD142 exposure. Unexpectedly, circulating EMP measured as CD144 or CD144+CD142+ increased significantly during atorvastatin treatment.

In Paper IV we investigated and characterized in vivo release of MP from 15 healthy volunteers administered lipopolysaccharide (LPS) in the presence of hydrocortisone with or without inhaled nitric oxide. MP from platelets (CD42a or CD41), endothelial cells (CD144 or CD62E) and monocytes (CD14) were studied. Nuclear content in MP was assessed (SYTO 13 binding) as well as HMGB1 exposure. Irrespective of treatment, LPS led to an increase in numbers of all MP, as well as the number of PMP and monocyte MP positive for anti-HMGB1 and SYTO 13.

Conclusions
We describe a flow cytometric method to measure MP in plasma, and we demonstrate that MP from platelets and endothelial cells respond differently to statin treatment, reflecting the complexity of MP formation. Furthermore, we show that experimental inflammation leads to elevated circulating MP, and that MP may be a source of extracellular HMGB1. MP may be used as biomarkers, an idea that deserves to be investigated more extensively in future studies.

ISBN 978-91-7549-057-1